Irritable Bowel Syndrome Trial, Recruiting NCT07688044 Sponsor: David Reed Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Irritable Bowel Syndrome Trial, Recruiting

NCT07688044
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 70 years old who have been diagnosed with Irritable Bowel Syndrome (IBS) based on recognised medical guidelines (Rome IV or V criteria)
  • People whose belly pain scores above a certain level, as measured by a standard questionnaire called PROMIS (a score above 12)

Who may not be able to join:

  • People who have another significant digestive or gut condition at the same time, such as coeliac disease or inflammatory bowel disease (IBD)
  • People who have another serious ongoing illness or abnormal test results that the trial doctors consider risky or that could affect the study results
  • People who have had major gut surgery in the past, such as bowel removal or a gastric bypass type procedure
  • People with a Body Mass Index (BMI) above 30 (confirm with trial site for how this is measured)
  • People who have had an active cancer diagnosis in the last 5 years, not including a type of minor skin cancer called basal cell cancer
  • People who are currently pregnant or breastfeeding
  • People who are currently in another clinical trial, or who have been in one within the past month
  • People who have used antibiotics or probiotics during the study period or within one month before it starts
  • People who have started a new medication less than 4 weeks before the study begins
  • People who have allergies to any ingredients used in the study (confirm with trial site for full ingredient list)
  • People who have a condition that weakens the immune system
  • People who are currently receiving treatment for an eating disorder, schizophrenia, psychosis, or another acute mental health condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
David Reed
Registry
ClinicalTrials.gov
Start date
16 March 2026
Est. completion
1 March 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in Dorsal Root Ganglion (DRG) neuron rheobase by chemostat supernatant; Change in Dorsal Root Ganglion (DRG) neuron rheobase by fecal supernatant

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov